MX2024004012A - Anticuerpos anti-galectina-9 y usos terapéuticos de estos. - Google Patents

Anticuerpos anti-galectina-9 y usos terapéuticos de estos.

Info

Publication number
MX2024004012A
MX2024004012A MX2024004012A MX2024004012A MX2024004012A MX 2024004012 A MX2024004012 A MX 2024004012A MX 2024004012 A MX2024004012 A MX 2024004012A MX 2024004012 A MX2024004012 A MX 2024004012A MX 2024004012 A MX2024004012 A MX 2024004012A
Authority
MX
Mexico
Prior art keywords
galectin
antibodies
therapeutic uses
tislelizumab
igg4
Prior art date
Application number
MX2024004012A
Other languages
English (en)
Spanish (es)
Inventor
Eric Elenko
Aleksandra Filipovic
Heather Paden
Christopher Korth
Srikumar Sahasranaman
Nageshwar Budha
Original Assignee
Puretech Lyt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Puretech Lyt Inc filed Critical Puretech Lyt Inc
Publication of MX2024004012A publication Critical patent/MX2024004012A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2024004012A 2021-10-01 2022-09-30 Anticuerpos anti-galectina-9 y usos terapéuticos de estos. MX2024004012A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163251227P 2021-10-01 2021-10-01
US202163277384P 2021-11-09 2021-11-09
PCT/US2022/077408 WO2023056461A1 (en) 2021-10-01 2022-09-30 Anti-galectin-9 antibodies and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
MX2024004012A true MX2024004012A (es) 2024-07-01

Family

ID=85783695

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004012A MX2024004012A (es) 2021-10-01 2022-09-30 Anticuerpos anti-galectina-9 y usos terapéuticos de estos.

Country Status (9)

Country Link
US (1) US20250269019A1 (enExample)
EP (1) EP4392068A4 (enExample)
JP (1) JP2024536201A (enExample)
KR (1) KR20240082393A (enExample)
AU (1) AU2022355201A1 (enExample)
CA (1) CA3233331A1 (enExample)
IL (1) IL311796A (enExample)
MX (1) MX2024004012A (enExample)
WO (1) WO2023056461A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084553A1 (en) * 2017-10-27 2019-05-02 New York University ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF
CN119033928A (zh) * 2019-05-01 2024-11-29 纽约大学 抗半乳糖凝集素-9抗体及其用途
WO2021022256A1 (en) * 2019-08-01 2021-02-04 New York University Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
US20230057071A1 (en) * 2019-12-20 2023-02-23 Novartis Ag Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome

Also Published As

Publication number Publication date
CA3233331A1 (en) 2023-04-06
EP4392068A4 (en) 2026-03-11
IL311796A (en) 2024-05-01
US20250269019A1 (en) 2025-08-28
WO2023056461A1 (en) 2023-04-06
AU2022355201A1 (en) 2024-04-04
EP4392068A1 (en) 2024-07-03
KR20240082393A (ko) 2024-06-10
JP2024536201A (ja) 2024-10-04

Similar Documents

Publication Publication Date Title
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
MX2020012286A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t.
CL2020003071A1 (es) Proteínas de unión multiespecíficas y mejoras con estas
MX2024008677A (es) Conjugados de camptotecina.
MX2019012811A (es) Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinacion.
MX2020012130A (es) Proteinas multiespecificas de union de direccionamiento a anhidrasa carbonica 9 (caix), anoctamina-1 (ano1), mesotelina, antigeno de superficie celular de trofoblasto (trop2), antigeno carcinoembrionario (cea) o claudina-18.2.
PH12018500815A1 (en) Antibody conjugates comprising toll-like receptor agonist
MY209796A (en) Fusion protein constructs for complement associated disease
PH12021550152A1 (en) Anti-cd112r compositions and methods
AR102879A1 (es) Métodos para el tratamiento de tumores cerebrales
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
PH12018550164A1 (en) Bcma binding molecules and methods of use thereof
WO2017152085A8 (en) Combination therapy with anti-cd73 antibodies
AR120147A1 (es) Anticuerpos anti-pd-l1 y conjugados anticuerpo-fármaco
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
MY208638A (en) Anti-steap1 antigen-binding protein
MX2022005618A (es) Metodos para tratar cancer que expresa la proteina del ligando 1 de muerte celular programada (pd-l1).
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
MX2024002238A (es) Anticuerpos anti-ccr8 y uso de los mismos.
JOP20220161A1 (ar) جسم مضاد لـ lilrb1 واستخداماته
MX2020006171A (es) Terapia de combinacion con anticuerpos anti interleucina-8 (il-8) y anticuerpos anti receptor de muerte programada (pd-1) para tratar cancer.
MX2024006743A (es) Unidad de union a antigeno ccr8 y usos de los mismos.